Key Highlights

● PCRX shares rose 44.40% to $36.39 in Thursday’s October 8 session and reached a 52-week high.

● Viatris agreed to acquire Pacira BioSciences for about $1.65 billion.

● The transaction centers on Pacira’s non-opioid pain-management portfolio, which sits within the push for alternatives to opioid-based analgesia.

● The gain came as the Nasdaq Composite fell about 1.25% and the Philadelphia Semiconductor index fell as much as about 4%.

Pacira BioSciences (NASDAQ:PCRX) was one of the standout gainers on Thursday, October 8, 2026, closing at $36.39 for a one-day advance of 44.40% and reaching a 52-week high. Unlike many of the session’s sharp movers, Pacira’s surge was tied to a clearly identified, company-specific catalyst: an agreement for the company to be acquired, which reset the stock toward the Economics of a negotiated Takeover rather than leaving it to trade purely on its standalone Business outlook.

The Viatris Agreement and the Non-Opioid Franchise

The driver was a deal with Viatris (NASDAQ:VTRS), which agreed to acquire Pacira BioSciences for about $1.65 billion. The transaction centers on Pacira’s non-opioid pain-management portfolio, an asset base that has positioned the company within the push to offer alternatives to opioid-based analgesia. Acquisitions of this kind typically carry a premium to the target’s prior trading level, and the combination of a defined deal value and a strategic rationale around the non-opioid Franchise is consistent with the kind of re-rating that drove the shares to a fresh 52-week high on the session.

How a Takeover Reprices a Stock

The market reaction fits the familiar pattern for an announced acquisition. When a buyer agrees to purchase a company, the target’s shares tend to move quickly toward the implied transaction terms, and much of the price adjustment is often concentrated in the single session when the agreement becomes public. A 44% jump to a 52-week high reflects that repricing dynamic, in which the stock begins to track deal-completion expectations rather than day-to-day operating sentiment. For Viatris, acquiring Pacira’s non-opioid pain Assets adds a differentiated portfolio to its lineup; for Pacira holders, the agreement crystallized a value for the business in a single step.

A Deal-Driven Move in a Risk-Off Session

Pacira’s advance also stood out against a session that was otherwise unfriendly to risk, underscoring how deal-driven moves can decouple from broader market direction. Thursday was a risk-off day for technology: the Nasdaq Composite fell about 1.25% to roughly 27,193 and the S&P 500 eased about 0.47% to around 7,765, while the Dow Jones Industrial Average edged up about 0.10% to near 51,232.

The dominant theme was a semiconductor and artificial-intelligence-infrastructure selloff, triggered by a report that OpenAI’s annualized Revenue was running roughly $20 billion below earlier estimates, which dragged the Philadelphia Semiconductor Index down as much as about 4%. A second theme was firmer oil, with WTI crude near $91 a barrel on Persian Gulf Supply concerns, while the 10-year Treasury Yield hovered near multidecade highs around 5.3%. A biopharmaceutical takeover is insulated from those currents, and Pacira’s gain owed to its own deal news rather than to any sector or macro tailwind.

Deal-Completion Risk Now Frames the Stock

An announced Acquisition changes the character of a stock’s risk. Once a deal is struck, the shares tend to trade on the probability and timing of completion, including factors such as regulatory review and closing conditions, rather than on the underlying operating story, and any gap between the current price and the implied deal terms reflects the market’s assessment of those completion risks. Pacira’s move was, unambiguously, an acquisition-driven re-rating.